MDGL
Madrigal Pharmaceuticals, Inc.
$471.75
-5.16
(-1.08%)
Mkt Cap
10.90B
Volume
312,984
52W Range
393.61-615
Sector
Healthcare
Beta
-1.05
EPS (TTM)
-12.89 USD
P/E Ratio
-45.32
Revenue (TTM)
1.28B USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 958.40M | 180.13M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (288.28M) | (465.89M) | (373.63M) | (295.35M) | (241.85M) | (202.24M) | (83.95M) | (32.81M) | (31.15M) | (26.39M) | (6.84M) | (86.16M) |
| EPS | -12.85 | -21.90 | -19.99 | -17.23 | -14.63 | -13.09 | -4.73 | -2.22 | -2.54 | -5.07 | -401.56 | -30.62 |
| Free Cash Flow | (190.02M) | (457.03M) | (325.71M) | (225.07M) | (184.13M) | (157.90M) | (41.80M) | (25.53M) | (22.44M) | (17.61M) | (71.50M) | (79.07M) |
| FCF / Share | -8.47 | -21.48 | -17.43 | -13.13 | -11.14 | -10.22 | -2.71 | -1.73 | -1.83 | -3.38 | -418.11 | -28.10 |
| Operating CF | (189.55M) | (455.57M) | (324.23M) | (224.86M) | (183.92M) | (157.56M) | (41.62M) | (25.51M) | (22.32M) | (17.61M) | (71.44M) | (78.92M) |
| Total Assets | 1.26B | 1.04B | 640.55M | 362.57M | 273.33M | 287.00M | 442.06M | 485.43M | 192.31M | 41.21M | 68.19M | 100.67M |
| Total Debt | 354.36M | 119.57M | 117.19M | 49.89M | 797,000 | 786,000 | 676,000 | 0 | 0 | 0 | 4.65M | 13.91M |
| Cash & Equiv | 198.69M | 100.02M | 99.92M | 331.55M | 36.27M | 54.00M | 46.70M | 57.38M | 148.63M | 40.50M | 34.97M | 46.02M |
| Book Value | 602.69M | 754.38M | 405.33M | 197.39M | 196.11M | 239.97M | 416.56M | 476.98M | 182.26M | 36.41M | 50.41M | 65.14M |
| Return on Equity | -0.48 | -0.62 | -0.92 | -1.50 | -1.23 | -0.84 | -0.20 | -0.07 | -0.17 | -0.72 | -0.14 | -1.32 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 364.25M | 311.34M | 321.08M | 287.27M | 212.80M | 137.25M | 103.32M | 62.17M | 14.64M | 0 | 0 | 0 |
| Net Income | (57.94M) | (94.39M) | (58.58M) | (114.19M) | (42.28M) | (73.24M) | (59.42M) | (106.96M) | (151.97M) | (147.54M) | (112.19M) | (98.74M) |
| EPS | -1.99 | -3.25 | -2.57 | -5.08 | -1.90 | -3.32 | -2.71 | -4.92 | -7.10 | -7.38 | -5.68 | -5.34 |
| Free Cash Flow | 19.08M | (171.28M) | (133.07M) | 78.99M | (47.05M) | (88.89M) | (104.68M) | (67.76M) | (140.08M) | (149.51M) | (80.97M) | (85.26M) |
| FCF / Share | 0.65 | -5.90 | -5.93 | 3.51 | -2.12 | -4.02 | -4.77 | -3.12 | -6.54 | -7.47 | -4.10 | -4.61 |
| Operating CF | 23.33M | (167.44M) | (133.46M) | 79.85M | (47.05M) | (88.89M) | (104.49M) | (66.98M) | (134.94M) | (149.16M) | (79.93M) | (84.92M) |
| Total Assets | 1.24B | 1.23B | 1.26B | 1.36B | 1.02B | 996.63M | 1.04B | 1.07B | 1.10B | 1.08B | 640.55M | 237.96M |
| Total Debt | 347.75M | 347.31M | 354.36M | 346.40M | 123.95M | 119.77M | 119.57M | 119.14M | 118.06M | 117.72M | 117.19M | 116.56M |
| Cash & Equiv | 292.73M | 232.19M | 198.69M | 295.69M | 186.19M | 183.65M | 100.02M | 232.68M | 494.60M | 622.52M | 99.92M | 62.05M |
| Book Value | 523.72M | 543.45M | 602.69M | 625.73M | 695.98M | 710.64M | 754.38M | 777.15M | 857.12M | 850.76M | 405.33M | 22.25M |
| Return on Equity | -0.11 | -0.17 | -0.10 | -0.18 | -0.06 | -0.10 | -0.08 | -0.14 | -0.18 | -0.17 | -0.28 | -4.44 |
MDGL News
Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 1,800 Madrigal Pharmaceuticals, Inc. $MDGL
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Rating of “Moderate Buy” by Analysts
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off
Allworth Financial LP Buys New Position in Madrigal Pharmaceuticals, Inc. $MDGL
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)